Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids

Prasad, Vikas; Steffen, Ingo G.; Pavel, Marianne; Denecke, Timm; Tischer, Elisabeth; Apostolopoulou, Konstantina; Pascher, Andreas; Arsenić, Ruža; Brenner, Winfried

doi:10.1186/s13550-015-0130-2

Cited by 22 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once the diagnosis is suspected, standardised characterisation of LC comprises several specific steps for evaluation that are described in Table 1 [III, B]. [4][5][6][7][8][9]18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] ThC is revealed by tumour-related symptoms, or due to functionally active tumours or by chance. [11][12][13] Diagnostic procedures, including core biopsy under ultrasonography guidance, or preferably through a thoracic computed tomography (CT) scan, or upfront surgery following the guidelines for thymic tumour diagnosis, should be carried out.…”

Section: Diagnosis and Pathology/molecular Biologymentioning

confidence: 99%

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

et al. 2021

View full text Add to dashboard Cite

Section: Diagnosis and Pathology/molecular Biologymentioning

confidence: 99%

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

et al. 2021

View full text Add to dashboard Cite

“…They included proliferation ( Ki67, NAP1L1, NOL3, TECPR2 ), growth factor signaling ( ARAF, BRAF, KRAS, RAF1 ), secretion ( TPH1, VMAT1 ), epigenetic remodeling ( NAP1L1, RNF41, RSF1 ) and somatostatin receptor expression ( SSTR1, 3, 4 and 5 ). Ki-67 is well-described in BPNET [ 7 ], as is growth factor expression and signaling [ 36 ], the synthesis and transport of serotonin [ 36 ], epigenetic regulation [ 37 ] and somatostatin receptor expression [ 38 ]. It has been previously suggested that circulating levels of SSTR5 could be a potential biomarker for lung NETs [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis

et al. 2017

View full text Add to dashboard Cite

No effective blood biomarker exists to detect and clinically manage bronchopulmonary (BP) neuroendocrine tumors (NET). We developed a blood-based 51 NET-specific transcript set for diagnosis and monitoring and evaluated clinical performance metrics. It accurately diagnosed the tumor and differentiated stable from progressive disease as determined by RECIST criteria. Gene expression was evaluated in: a) publicly available BPNET transcriptomes (GSE35679); b) two BPNET cell-lines; and c) BPNET tissue with paired blood (n = 7). Blood gene expression was assessed in 194 samples including controls, benign lung diseases, malignant lung diseases and small bowel NETs. A separate validation study in 25 age- and gender-matched BPNETs/controls was performed. Gene expression measured by real-time PCR was scored (0–100%; normal: < 14%). Regression analyses, Principal Component Analysis (PCA), hierarchical clustering, Fisher's and non-parametric evaluations were undertaken. All 51 genes were identified in BPNET transcriptomes, tumor samples and cell-lines. Significant correlations were evident between paired tumor and blood (R2:0.63–0.91, p < 0.001). PCA and hierarchical clustering identified blood gene expression was significantly different between lung cancers and benign diseases, including BPNETs. Gene expression was highly correlated (R2: 0.91, p = 1.7 × 10-15) between small bowel and BPNET. For validation, all 25 BPNETs were positive compared to 20% controls (p < 0.0001). Scores were significantly elevated (p < 0.0001) in BPNETs (57 ± 28%) compared to controls (4 ± 5%). BPNETs with progressive disease (85 ± 11%) exhibited higher scores than stable disease (32 ± 7%, p < 0.0001). Blood measurements accurately diagnosed bronchopulmonary carcinoids, distinguishing stable from progressive disease. This marker panel will have clinical utility as a diagnostic liquid biopsy able to define disease activity and progression in real-time.

show abstract

“…31 For the few studies available, a median tumor detection rate of 90% (range, 79%-100%) with Gallium-68 PET imaging of patients with lung typical/atypical carcinoids has been reported (see Supplemental Figure 2 in the online version). 10,[32][33][34][35][36][37][38][39] Use of Gallium-68 SSTRbased PET alongside 18 F-fludeoxyglucose (FDG) PET, a measure of…”

Section: Somatostatin Receptors and Sstr Imaging In Lung Typical/atypical Carcinoidsmentioning

confidence: 99%

“…Institutional guidelines should be developed and followed for possible PRRT side effects, including exacerbation of hormonal symptoms such as hypoglycemia, nausea, vomiting, and, in rare circumstances, carcinoid crisis. 32 Pericleous et al, 33 Kumar et al, 34 Jindal et al, 35 Venkitaraman et al, 10 Prasad et al, 36 Ambrosini et al, 37 Lamarca et al, 38…”

Section: Patient Statusmentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids

Naraev

Ramirez

Kendi

et al. 2019

Clinical Lung Cancer

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NEN) are a family of malignancies of diverse origin, including the lung, gastrointestinal tract, and pancreas. Lung NEN include well differentiated neuroendocrine tumors (NET) classified as typical carcinoids or atypical carcinoids, and poorly differentiated neuroendocrine carcinomas classified as small-cell lung carcinoma or large-cell neuroendocrine carcinoma. According to a recent analysis of a large, population-based registry, approximately one-third of all patients with lung typical/atypical carcinoids have distant metastases at diagnosis, and median survival for these patients is 24 months. At present, only 1 therapy is approved by the US Food and Drug Administration (FDA) for patients with advanced lung typical/atypical carcinoids, everolimus, indicating a clear need for more treatment options in this patient population.Although not yet supported by results from randomized prospective trials, somatostatin analogues are considered an acceptable treatment option for patients with lung typical/atypical carcinoids expressing somatostatin receptors. Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE was recently approved by the FDA for the treatment of gastroenteropancreatic NET; however, the role of PRRT in patients with lung typical/atypical carcinoids remains unclear, because they were not included in the pivotal NETTER-1 (Neuroendocrine Tumors Therapy) trial. Herein we provide a comprehensive review of the available clinical evidence for efficacy and safety of PRRT in patients with lung typical/atypical carcinoids. On the basis of the preliminary evidence of efficacy and the consistent safety profile in this patient group, we propose that experienced multidisciplinary NET teams may consider PRRT alongside everolimus as an option for patients with advanced somatostatin receptor-positive lung typical/atypical carcinoids whose disease is progressing during first-line treatment with somatostatin analogues.

show abstract

Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids

Abstract: Background: To assess the role of somatostatin receptor (SR) PET/CT using Ga-68 DOTATOC or DOTATATE in staging and restaging of typical (TC) and atypical (AC) lung carcinoids.

Cited by 22 publications

References 24 publications

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis

Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids

Contact Info

Product

Resources

About